Plain-English translation of NCT06843148 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing niacin, a form of vitamin B3, as a treatment for metabolic dysfunction-associated steatotic liver disease (a condition where fat builds up in your liver). The study will compare niacin to a placebo (a dummy pill) over 12 weeks to see if the medication helps your body store fat in fat tissue instead of letting it accumulate in your liver.
Fatty liver disease is a growing health problem with few treatment options. Researchers believe this medication may work by redirecting fat away from your liver, potentially reducing inflammation and damage.
You likely qualify if…
You likely don't qualify if…
You will take either niacin or placebo once daily with your largest meal for 12 weeks, then switch to the other treatment for another 12 weeks (with a 4-week break in between). Four times during the study, you will attend 9-hour visits where you'll eat a test meal, have blood drawn, and receive imaging scans (MRI and PET scans) to measure how your body is handling fat.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
Canada
Sponsor
Université de Sherbrooke
Collaborators
CHU de Quebec-Universite Laval, Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Enrollment target
~36 participants
Started
June 2026
Primary completion
March 2030
Age range
20 Years – 80 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Frédérique Frisch
Université de Sherbrooke
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.